PROBING DRUG RELATED MENTAL DISORDERS OF AGING

探索与药物相关的衰老精神障碍

• 批准号: 6330292
• 负责人: IRA R KATZ
• 金额: $ 45.37万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 2003-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6330292
• 关键词: aging; antihypercholesterolemic agent; antihyperlipoproteinemic agent; behavior disorders; behavioral /social science research tag; clinical research; cognition disorders; comorbidity; disease /disorder etiology; drug adverse effect; drug interactions; geriatrics; human old age (65+); human subject; mood disorders; naproxen; psychopharmacology; sertraline

Adverse effects of medications prescribed for elderly patients are common causes of the mental disorders of aging. Therefore, studies of the cognitive, affective, and behavioral symptoms that result from the administration of centrally-acting medications can provide information about the symptoms that characterize the toxic encephalopathies. From a practical perspective, they can provide clinicians and patients with information on the risks associated with use of the tested medications that could facilitate the prevention of disability. Accordingly, we are proposing to conduct randomized, double-blind, placebo-controlled challenge studies in which we will administer commonly prescribed medications for a period of several weeks to healthy, medically stable elderly volunteers. We will test for effects of active medications versus placebo with weekly tests of cognition, depression, other mood states, and sleepiness/alertness, and with daily self-reports of events and of both positive and negative affects. The medications to be studied were selected because they are commonly used, sufficiently safe to allow administration to elderly volunteers, and are suspected as causes of cognitive or affective toxicity. We propose two studies: Study I will compare the effects of 5 weeks of metoclopramide (up to 40 mg/day), sertraline (up to 200 mg/day), naproxen (up to 1000 mg/day), and placebo. Study II will compare 14 weeks of simvastatin (up to 20 mg/day) with placebo. Analyses will include modeling using random regression models. The hypotheses to be tested are that the medications under investigation can cause behavioral toxicity manifest by changes in cognitive performance assessed through weekly assessments; depressive or related symptoms manifest through weekly clinical interviews or self- reports on depression and behavioral rating scales; and increased negative affect and/or decreased positive affect as assessed through daily self-reports. We will also explore the impact of medications on daily reports of positive or negative events and on the relationship between daily events and daily affect.

针对老年患者规定的药物的不利影响是 衰老精神障碍的常见原因。 因此，研究 由 中央作用药物的管理可以提供信息 关于特征有毒脑病的症状。 从 一个实用的角度，他们可以为临床医生和患者提供 有关使用测试药物的风险的信息 这可能有助于预防残疾。 因此，我们是 提议进行随机，双盲，安慰剂对照 挑战研究我们将经常规定 几周的药物以健康，医学稳定 老年志愿者。 我们将测试活跃药物的影响 与安慰剂相对于安慰剂，每周进行认知，抑郁和其他心情测试 状态，嗜睡/机敏，以及每天的事件自我报告 以及正面和负面影响。 药物是 选择了研究，因为它们通常使用，足够安全 允许对老年志愿者进行管理，并被怀疑为 认知或情感毒性的原因。 我们提出了两项​​研究： 研究我将比较5周的甲氧氯普胺的影响（高达40个 mg/day），舍曲林（最多200 mg/day），萘普生（高达1000 mg/天）， 和安慰剂。 研究II将比较14周的辛伐他汀（最多20个 mg/day）安慰剂。 分析将包括使用随机建模 回归模型。 要测试的假设是药物 在研究中可能导致行为毒性通过变化表现出来 通过每周评估评估认知表现；抑郁 或相关症状通过每周的临床访谈或自我表现出来 关于抑郁和行为评级量表的报告；并增加 通过评估的负面影响和/或降低积极影响 每日自我报告。 我们还将探讨药物对 每日报道正面或负面事件以及关系 在日常事件和日常影响之间。